Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
$6.05
-1.1%
$5.94
$5.26
$11.38
$242.33M0.67553,952 shs424,067 shs
AtriCure, Inc. stock logo
ATRC
AtriCure
$22.30
+1.4%
$27.82
$20.19
$59.61
$1.06B1.41714,914 shs899,399 shs
Integer Holdings Co. stock logo
ITGR
Integer
$113.97
-0.2%
$114.74
$69.40
$123.99
$3.82B1.12335,044 shs206,477 shs
NuVasive, Inc. stock logo
NUVA
NuVasive
$39.75
$39.64
$35.17
$49.53
$2.08B1.071.16 million shsN/A
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
+3.90%+0.66%-12.20%+0.49%-33.04%
AtriCure, Inc. stock logo
ATRC
AtriCure
+6.33%-0.99%-20.32%-33.17%-55.11%
Integer Holdings Co. stock logo
ITGR
Integer
+0.90%+3.86%-4.06%+7.98%+43.63%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.00%0.00%0.00%0.00%-4.95%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
4.4563 of 5 stars
3.52.00.04.22.73.31.3
AtriCure, Inc. stock logo
ATRC
AtriCure
3.6473 of 5 stars
4.54.00.00.01.92.50.6
Integer Holdings Co. stock logo
ITGR
Integer
1.4962 of 5 stars
1.31.00.00.02.52.53.1
NuVasive, Inc. stock logo
NUVA
NuVasive
2.0617 of 5 stars
3.30.00.00.00.00.03.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
3.00
Buy$14.25135.54% Upside
AtriCure, Inc. stock logo
ATRC
AtriCure
3.00
Buy$49.78123.22% Upside
Integer Holdings Co. stock logo
ITGR
Integer
2.67
Moderate Buy$120.505.73% Upside
NuVasive, Inc. stock logo
NUVA
NuVasive
2.50
Moderate Buy$51.3329.14% Upside

Current Analyst Ratings

Latest ITGR, ATRC, NUVA, and ANGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/10/2024
Integer Holdings Co. stock logo
ITGR
Integer
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$130.00
5/2/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$57.00 ➝ $49.00
5/2/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.00
5/2/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$46.00 ➝ $40.00
4/26/2024
Integer Holdings Co. stock logo
ITGR
Integer
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$130.00
4/23/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$32.00
4/15/2024
Integer Holdings Co. stock logo
ITGR
Integer
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$105.00 ➝ $135.00
4/10/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00
4/9/2024
Integer Holdings Co. stock logo
ITGR
Integer
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$123.00 ➝ $139.00
4/5/2024
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$12.00
3/28/2024
Integer Holdings Co. stock logo
ITGR
Integer
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$105.00 ➝ $130.00
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
$324.01M0.75$1.06 per share5.72$9.64 per share0.63
AtriCure, Inc. stock logo
ATRC
AtriCure
$414.60M2.56N/AN/A$9.84 per share2.27
Integer Holdings Co. stock logo
ITGR
Integer
$1.63B2.34$8.13 per share14.01$45.58 per share2.50
NuVasive, Inc. stock logo
NUVA
NuVasive
$1.23B1.70$4.96 per share8.01$17.02 per share2.34

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
-$52.44M-$4.84N/AN/AN/A-60.21%-3.48%-2.68%7/10/2024 (Estimated)
AtriCure, Inc. stock logo
ATRC
AtriCure
-$30.44M-$0.80N/AN/AN/A-8.98%-7.85%-6.05%7/23/2024 (Estimated)
Integer Holdings Co. stock logo
ITGR
Integer
$90.65M$2.8939.4418.561.656.01%11.25%5.69%7/25/2024 (Estimated)
NuVasive, Inc. stock logo
NUVA
NuVasive
$40.41M$0.5079.5015.35N/A2.32%12.17%4.88%N/A

Latest ITGR, ATRC, NUVA, and ANGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024Q1 2024
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.23-$0.25-$0.02-$0.22$106.86 million$108.90 million      
4/25/2024Q1 2024
Integer Holdings Co. stock logo
ITGR
Integer
$1.12$1.14+$0.02$1.69$412.78 million$414.80 million      
4/4/2024Q3 2024
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
-$0.14-$0.16-$0.02$4.41N/AN/A
2/15/2024Q4 2023
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.22-$0.21+$0.01-$0.21$103.68 million$106.50 million      
2/15/2024Q4 2023
Integer Holdings Co. stock logo
ITGR
Integer
$1.34$1.39+$0.05$2.00$409.04 million$413.15 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
N/AN/AN/AN/AN/A
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
Integer Holdings Co. stock logo
ITGR
Integer
N/AN/AN/AN/AN/A
NuVasive, Inc. stock logo
NUVA
NuVasive
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
N/A
2.29
1.62
AtriCure, Inc. stock logo
ATRC
AtriCure
0.16
4.00
2.83
Integer Holdings Co. stock logo
ITGR
Integer
0.76
3.32
2.01
NuVasive, Inc. stock logo
NUVA
NuVasive
0.50
1.25
0.65

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
89.43%
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
Integer Holdings Co. stock logo
ITGR
Integer
99.29%
NuVasive, Inc. stock logo
NUVA
NuVasive
N/A

Insider Ownership

CompanyInsider Ownership
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
5.10%
AtriCure, Inc. stock logo
ATRC
AtriCure
3.20%
Integer Holdings Co. stock logo
ITGR
Integer
2.00%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.53%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
81540.06 million38.01 millionOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,20047.59 million46.07 millionOptionable
Integer Holdings Co. stock logo
ITGR
Integer
10,50033.50 million32.83 millionOptionable
NuVasive, Inc. stock logo
NUVA
NuVasive
3,00052.45 million52.17 millionOptionable

ITGR, ATRC, NUVA, and ANGO Headlines

SourceHeadline
Surgical robots are ‘gift that will keep on giving,’ ortho firms saySurgical robots are ‘gift that will keep on giving,’ ortho firms say
finance.yahoo.com - May 9 at 3:39 PM
Globus Medical: Sell Rating Justified by Integration Risks and Conservative Guidance Despite Strong QuarterGlobus Medical: Sell Rating Justified by Integration Risks and Conservative Guidance Despite Strong Quarter
markets.businessinsider.com - May 8 at 7:38 PM
Globus Medicals Q1 sales soar 119.3%: 6 notesGlobus Medical's Q1 sales soar 119.3%: 6 notes
beckersspine.com - May 8 at 7:38 PM
Trauma Products Market Share, Analysis, Size, Prominent Players, and Forecast 2024 to 2032Trauma Products Market Share, Analysis, Size, Prominent Players, and Forecast 2024 to 2032
taiwannews.com.tw - May 3 at 5:25 AM
Stem cell therapy Market Shaping Strategies, The Power of Future Market Size in Decision-MakingStem cell therapy Market Shaping Strategies, The Power of Future Market Size in Decision-Making
taiwannews.com.tw - May 2 at 1:42 PM
Global Scaffold Technology Market is set to expand at a CAGR of 11.3% until 2034 | Future Market Insights, Inc.Global Scaffold Technology Market is set to expand at a CAGR of 11.3% until 2034 | Future Market Insights, Inc.
prnewswire.co.uk - April 30 at 7:04 AM
Intraoperative Neurophysiological Monitoring Market Set for Significant Expansion, Valued at USD 3.2 Billion in 2023Intraoperative Neurophysiological Monitoring Market Set for Significant Expansion, Valued at USD 3.2 Billion in 2023
pharmiweb.com - April 29 at 9:02 AM
Orthopedic Devices Market Future of Augmented Reality in Market Research Opportunities and ChallengesOrthopedic Devices Market Future of Augmented Reality in Market Research Opportunities and Challenges
taiwannews.com.tw - April 26 at 12:41 PM
Bone Void Fillers Market Size, Share, Key Players, Revenue, Demand, and Forecast to 2024 to 2032Bone Void Fillers Market Size, Share, Key Players, Revenue, Demand, and Forecast to 2024 to 2032
taiwannews.com.tw - April 19 at 1:56 AM
Regenerative Medicine Market Will Grow Nearly USD 194.9 Billion At A Rate Of 19.4% By 2032Regenerative Medicine Market Will Grow Nearly USD 194.9 Billion At A Rate Of 19.4% By 2032
pharmiweb.com - April 18 at 10:34 AM
SMAIO Publishes its 2023 Annual ResultsSMAIO Publishes its 2023 Annual Results
finance.yahoo.com - April 17 at 6:36 PM
This Week in Chancery Court: Poison Pill Ruling, NuVasiveThis Week in Chancery Court: Poison Pill Ruling, NuVasive
news.bloomberglaw.com - April 15 at 8:58 AM
Bone Grafting Screw Market Segmentation Analysis, Share, Trends, Size, Key Players, and Forecast 2024 to 2032Bone Grafting Screw Market Segmentation Analysis, Share, Trends, Size, Key Players, and Forecast 2024 to 2032
taiwannews.com.tw - April 12 at 7:59 AM
10 robots used in spine surgery10 robots used in spine surgery
beckersspine.com - April 10 at 6:27 PM
Global Polymeric Biomaterials Market 10 Year Forecast Report 2024-2034, with Company Profiles of the Top 10+ Major Market PlayersGlobal Polymeric Biomaterials Market 10 Year Forecast Report 2024-2034, with Company Profiles of the Top 10+ Major Market Players
finance.yahoo.com - April 9 at 10:20 AM
Accelus adds 2 leadersAccelus adds 2 leaders
beckersspine.com - April 3 at 3:20 PM
$14.3 Bn Spinal Implants Markets: Devices, Biologics, Stimulators, VCF, Spinal Decompression, Fusion, Non-Fusion - Global Forecast to 2028$14.3 Bn Spinal Implants Markets: Devices, Biologics, Stimulators, VCF, Spinal Decompression, Fusion, Non-Fusion - Global Forecast to 2028
finance.yahoo.com - April 3 at 10:19 AM
Spine Pain Market Expected to Reach US$12.47 Billion by 2033 with CAGR of 5%Spine Pain Market Expected to Reach US$12.47 Billion by 2033 with CAGR of 5%
fmiblog.com - April 2 at 2:16 PM
Globus Medical director sells $550K in stockGlobus Medical director sells $550K in stock
beckersspine.com - March 20 at 4:48 PM
Orthopedic Navigation Systems Market Will Increase USD 8.9 Billion By 2033 with 12.7% CAGROrthopedic Navigation Systems Market Will Increase USD 8.9 Billion By 2033 with 12.7% CAGR
pharmiweb.com - March 14 at 9:11 AM
Wrist Replacement Orthopedic Devices Market on Course to Achieve USD 618.9 Million by 2033 | Market.usWrist Replacement Orthopedic Devices Market on Course to Achieve USD 618.9 Million by 2033 | Market.us
pharmiweb.com - March 13 at 10:23 PM
Minimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarkets™Minimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarkets™
prnewswire.co.uk - March 13 at 10:23 PM
UK reinstates modified MAGEC X system for scoliosis treatmentsUK reinstates modified MAGEC X system for scoliosis treatments
msn.com - March 13 at 5:22 PM
Pediatric Orthopedic Implant Market Forecast Highlights 7.4% Growth Rate, Reaching USD 7.1 Billion by 2033Pediatric Orthopedic Implant Market Forecast Highlights 7.4% Growth Rate, Reaching USD 7.1 Billion by 2033
pharmiweb.com - March 12 at 4:16 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AngioDynamics logo

AngioDynamics

NASDAQ:ANGO
AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
AtriCure logo

AtriCure

NASDAQ:ATRC
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Integer logo

Integer

NYSE:ITGR
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
NuVasive logo

NuVasive

NASDAQ:NUVA
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.